The RATIONALE-301 (A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of tislelizumab Versus Sorafenib as First-Line Treatment in Patients With Unresectable HCC) trial found tislelizumab, a programmed cell death 1 (PD-1) antibody, to be noninferior to sorafenib (27). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.